JMP moves Myriad Genetics to strong buy

Myriad Genetics, Inc. was upgraded to strong buy from market outperform by JMP Securities analyst Charles C. Duncan. JMP increased its price target to $29 from $25. The company announced positive financial results for second-quarter 2006 that beat the analyst's and consensus estimates on top and bottom lines. JMP anticipates continued growth in Predictive Medicine revenue estimates for fiscal year 2006 and outer years. Shares of the Salt Lake City biopharmaceutical company were up $1.82, or 8.08%, at $24.35 on volume of 1,073,683 shares versus the three-month running average of 343,233 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.